Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : EQT Life Sciences
Deal Size : $56.0 million
Deal Type : Series A Financing
EQT Life Sciences Leads €54 Million Series A Financing of ATB Therapeutics
Details : The proceeds will fund development of oncology and immunology therapeutics derived from innovative antibody payload platform, including novel antibody therapies for oncology and auto-immune disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : EQT Life Sciences
Deal Size : $56.0 million
Deal Type : Series A Financing